Please login to the form below

Not currently logged in
Email:
Password:

Eisai shares drop on failure of Aricept successor

Shares in Japan-based pharmaceutical company Eisai dropped 3.1 per cent to reach JPY 4,960 (USD 43.21) due to the failure of entacapone, the company's successor product to the Alzheimer's disease treatment, Aricept (donepezil).

Shares in Japan-based pharmaceutical company Eisai dropped 3.1 per cent to reach JPY 4,960 (USD 43.21) due to the failure of entacapone, the company's successor product to the Alzheimer's disease treatment, Aricept (donepezil).

One of three studies on entacapone, showed no advantage over a placebo, according to a company statement. As a result, the regulatory filing for the drug has been set back until 2009.

Eisai also revealed it would delay applying for FDA approval of its investigational breast cancer drug, E-7389. The company will now file in Q1 2008, instead of in the current quarter. If successful, E-7389 will be Eisai's first new product on the US market since 1998.

Sales of Aricept added to Eisai's recent posting of a 20 per cent profit rise in Q3 FY07. As a result, this is Eisai's biggest-selling product, the US patent of which will run out in  2010. Q3 FY07 sales for Aricept were JPY 73.5bn (USD 640.3m).

According to Daiwa Institute of Research analysts, the delay in developing entacapone would make it very difficult for Eisai to replace lost Aricept sales. They said they had been expecting the experimental drug to recover half of Aricept sales after its US patent expires in 2010.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics